The annual report in 2014 of Tasly showed that the revenue was 12.57 billion Yuan, with a yearly growth of 13.24%. The net profit attributable to parent company increased by 24.61% up to 1.37 billion Yuan, and the profit excluding non-recurring item was 1.346 billion Yuan with a growth of 31.9%. The gross margin has grown by 0.94 pct. to 37.48%. Overall speaking, the company has maintained steadily growing trend and high dividend return. Seen from the categories of businesses, the revenue of pharmaceutical manufacturing was 6.05 billion Yuan, the revenue of pharmaceutical distribution and retail business was 6.47 billion Yuan and the growth dropped to 6.6%, caused by the company’s adjustment of commercial channels.

The company holds prominent competitive advantages. It has a strong ability of vertical integration among traditional Chinese medicine(TCM) industry and established an end-to-end modern industry chain, which conforms to the standardized management including GAP, GEP, GMP, GLP, GCP, and GSP, in possession of leading control force and advantages of supply chain.

Tasly has established the new mode of TCM multi-fractions research and development and turn to a system of patent protection. Meanwhile, it has abundant product lines and most of them are at a fast growth. Moreover, Tasly has established integrated marketing network, the e-business channel will inject new vitality for its pharmaceutical distribution and retail business.

The company first carried forward the process of internationalization of TCM, and improved western medicine’s recognition to TCM by establishing medicinal materials bases, improving production standard of TCM and boosting evidence-based research. Danshen’s passing global phase III clinical trial is a big probability event, and it is expected to pass FDA certification in future, which may help it enter into the third rapid development period. Tasly has leading experience in the internationalization of TCM. Not only its own products will welcome the global market, but also the company is hopeful to hone into the platform for internationalization of domestic enterprises of TCM, so as to achieve further appreciation.

"Buy" rating for the leading position in modernization and internationalization of TCM

The company holds leading position in the modernization of TCM, possessing creativity as well as international strategic perspectives. Its sufficient product lines and the worldwide expansion strategy will boost the growth, the denotation expansion is hopefully to accelerate. Meanwhile, the major shareholders and the management are heavily involved in the directional add-issuance,which also demonstrates their optimism and confidence. We grant it 38X 2015EPS, and the target price can be CNY 64.62, with “Buy” rating initially. (Closing price as at 10 April 2015)
### Historical P/E Valuation

![Graph showing historical P/E valuation](image)

Source: Bloomberg, Phillip Securities (HK) Research

### Steadily growing performance in 2014

The annual report in 2014 of Tasly showed that the revenue was 12.57 billion Yuan, with a yearly growth of 13.24%. The net profit attributable to parent company increased by 24.61% up to 1.37 billion Yuan, and the profit excluding non-recurring item was 1.346 billion Yuan with a growth of 31.9%. Due to the rise in the percentage of pharmaceutical manufacturing, the gross margin has grown by 0.94 pct. to 37.48%. The company also has declared the profit distribution plan of 0.39 Yuan per share. Overall speaking, the company has maintained steadily growing trend and high dividend return.

### Continually rapid growth trend (RMB:mn)

![Graph showing revenue and adjusted net income growth](image)

Source: Company report, Phillip Securities (HK) Research

Seen from the categories of businesses, the revenue of pharmaceutical manufacturing was 6.05 billion Yuan with a growth of 23%, among which the sale of Danshen Compound Dripping Pill(Danshen) was estimated to be more than 2.5 billion Yuan with a growth of 10% - 15%, accounting for 40%+ of total amount. The growth of the second variety Yangxue Qingnai Granule was about 20% and key varieties such as sibilin capsules, Qishen Yiqi Dripping Pill, Chuanxinlinian Lactone Dripping Pill, Yiqi Fumai Injection kept the growth at over 30%. Although the gross margin went down somewhat, it was still up to 71%. 
The revenue of pharmaceutical distribution and retail business was 6.47 billion Yuan and the growth dropped to 6.6%, caused by the company’s adjustment of commercial channels; however, the gross margin increased by almost 1 pct. up to 6.13% for the reason that the company increased the business of direct selling to hospitals.

In addition, the expense ratio were 23.24% with a growth of 0.6 pct., mainly caused by the increase in borrowing due to the denotation expansion, and the financial expense ratio went up by nearly 1 pct. Nevertheless, recently the company has completed the financing of 1.6 billion Yuan by directional add-issuance, which will, to some degree, relieve the financial pressure.

**Prominent competitive advantages**

Tasly has established its leading role in modernization and internationalization of TCM industry in Mainland, and achieved the CAGR of 27% and 24.3% for its revenue and net profit from 2005 to 2014, which mainly rely on below competitive advantages:

First of all, the company has a strong ability of vertical integration among TCM industry and established an end-to-end modern industry chain, which conforms to the standardized management including GAP, GEP, GMP, GLP, GCP, and GSP, in possession of leading control force and advantages of supply chain. The company has set up standardized planting bases for dan-shen root and pseudo-ginseng in Shangluo of Shanxi, Yunnan and Xinhuang of Hunan, and the former is the first base of medicinal material resources in China which meets GAP standard and passes the EU certification.

Secondly, it has prominent advantages of research and development technology and patent system. Tasly has established the new mode of TCM multi-fractions research and development. It also first puts forward and formulates the new GEP standard for active composition of traditional Chinese medicine, and successfully applies the quality control technique of multiple chromatographic fingerprinting to quality control of traditional Chinese medicine. At the same time, the company turns to a system of patent protection, which is a change of patent protection from single industry to whole industrial chain, a change of patent protection from focus on China to internationalization and a change of focus on new drug protection to extension of term of protection for current products together with new drug protection. By the end of 2014, the company had 1,321 patents in total with
1,179 patents for invention, 436 patents for Danshen, and 94 patents for Yangxue Qingnao Granule.

In addition, the company has abundant product lines and develops more than 10 varieties in the field including Cardiovascular and cerebrovascular, digestive system, antitumor, and anti-cold, which respectively has the output of over 100 million Yuan and most of which are at a fast growth. The Yiqi Fumai Injection has been added into the supplementary lists of medical insurance system in half of provinces in China, and if it is added into the national health insurance, it will promingly become the product with an output of more than 1 billion. Salvianolic acid Injection is also added into health insurance in many provinces, and as the treatment guidelines drug for acute myocardial infarction in China, its capacity has been expanded three times. And at present, 95% of patients suffering from myocardial infarction cannot receive timely treatment, which shows the market space is quite wide.

Thirdly, the company has established integrated marketing network, formed acknowledged experts, consultants and prescription doctors group who are familiar with company products, and built long-term cooperation partner relationship with more than 200 first-grade business dealers and more than 2,000 second-grade business dealers, covering more than 60,000 drugstores, more than 60,000 basic level medical treatment organizations, and nearly 20,000 sales terminals of hospitals. And the company has set up a medical e-business platform, and the ranking of Tasly flagship store has ascended to No. 15 in Tmall OTC drug category. The company has launched "Door-to-Door service for diabetes mellitus" in Tianjin, collecting 5,800 service objects in 2014, with the repeat purchase rate as high as 97%, and it will continue to collect 30,000 service objects in 2015. We believe that the e-business channel will inject new vitality for pharmaceutical distribution and retail business.

**Internationalization of TCM enters the critical period**

The company first carried forward the process of internationalization of TCM, and improved western medicine’s recognition to TCM by establishing medicinal materials bases, improving production standard of TCM and boosting evidence-based research.

The main element of Danshen Compound Dripping Pills are danshen, pseudoginseng, and borneol, indication for coronary heart disease and angina, which has already gone through the two rapid development periods among 1994-
2002 and 2010 till now, with the CAGR as high as 75% and 18% respectively. At present, global multi-center clinical trial of Danshen has already come into the critical period, phase III clinical trial of North America has come into the ending phase. From the perspective of long term, we think, Danshen’s passing global phase III clinical trial is a big probability event, and it is expected to pass FDA certification in future, which may help it enter into the third rapid development period.

According to statistics, nearly 85 million American adults suffer from at least one kind of cardiovascular disease. Up to 2030, about 44% of total population in America will suffer from one cardiovascular disease. In recent twenty years, there is only one new drug of chronic angina disease coming into market in America, and if Danshen could appear in the market as therapeutic drug in America, it will improve the temporary shortage plight of stranded against heart disease, and become the first global vegetable drug for preventing and curing for coronary heart disease and angina with huge international market.

### Cardiovascular disease death in the USA

<table>
<thead>
<tr>
<th>Category</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coronary heart disease</td>
<td>52.5%</td>
</tr>
<tr>
<td>Paralytic stroke</td>
<td>17.1%</td>
</tr>
<tr>
<td>Congestive heart failure</td>
<td>11.4%</td>
</tr>
<tr>
<td>High blood pressure</td>
<td>7.4%</td>
</tr>
<tr>
<td>Disease of artery</td>
<td>3.9%</td>
</tr>
<tr>
<td>Others</td>
<td>3.5%</td>
</tr>
</tbody>
</table>

Source: National Center for Health Statistics, Phillip Securities (HK) Research

Moreover, the company is going to accelerate the application process of FDA-IND for Salvianolic acid Injection, Chuanxinlian Lactone Dripping Pill, Silibinin capsule and so on. We think Tasly has leading experience in the internationalization of TCM. Not only its own products will welcome the global market, but also the company is hopeful to hone into the platform for internationalization of domestic enterprises of traditional Chinese medicines, so as to achieve further appreciation.

### Catalyst

- New products are put into market rapidly with more bidding in various provinces;
- New national medical insurance catalog may launch and Tasly’s products can benefit from that;
- Accelerated denotative expansion;
- Danshen passed global phase III clinical trial.

### Risks

- Drug price reduces;
- Adverse drug reaction;
- Price of raw materials increases;
- Uncertainty of approval for new drug.
## Financials

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Valuation Ratios</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Price Earnings</td>
<td>66.86</td>
<td>46.55</td>
<td>37.73</td>
<td>29.29</td>
<td>24.01</td>
</tr>
<tr>
<td>Price to Book</td>
<td>12.12</td>
<td>13.30</td>
<td>10.63</td>
<td>6.78</td>
<td>5.66</td>
</tr>
<tr>
<td>Dividend Yield</td>
<td>0.20%</td>
<td>0.70%</td>
<td>0.78%</td>
<td>1.02%</td>
<td>1.24%</td>
</tr>
<tr>
<td><strong>Per share data (CNY)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPS Adjusted</td>
<td>0.75</td>
<td>1.07</td>
<td>1.32</td>
<td>1.70</td>
<td>2.07</td>
</tr>
<tr>
<td>Book Value Per Share</td>
<td>4.11</td>
<td>3.74</td>
<td>4.68</td>
<td>7.35</td>
<td>8.80</td>
</tr>
<tr>
<td>Dividends Per Share</td>
<td>0.10</td>
<td>0.35</td>
<td>0.39</td>
<td>0.51</td>
<td>0.62</td>
</tr>
<tr>
<td><strong>Growth &amp; Margin</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue growth</td>
<td>-</td>
<td>18.79%</td>
<td>13.29%</td>
<td>15.47%</td>
<td>15.46%</td>
</tr>
<tr>
<td>Gross profit growth</td>
<td>-</td>
<td>27.69%</td>
<td>16.35%</td>
<td>22.04%</td>
<td>18.62%</td>
</tr>
<tr>
<td>Net profit growth</td>
<td>-</td>
<td>43.04%</td>
<td>24.36%</td>
<td>32.73%</td>
<td>23.36%</td>
</tr>
<tr>
<td>Gross Margin</td>
<td>33.54%</td>
<td>36.05%</td>
<td>37.02%</td>
<td>39.13%</td>
<td>40.20%</td>
</tr>
<tr>
<td>Operating Margin</td>
<td>12.56%</td>
<td>14.01%</td>
<td>16.18%</td>
<td>17.63%</td>
<td>18.70%</td>
</tr>
<tr>
<td>Net Profit Margin</td>
<td>8.30%</td>
<td>9.99%</td>
<td>10.97%</td>
<td>12.61%</td>
<td>13.47%</td>
</tr>
<tr>
<td>Dividend Payout Ratio %</td>
<td>13.42%</td>
<td>32.71%</td>
<td>29.55%</td>
<td>29.99%</td>
<td>29.89%</td>
</tr>
<tr>
<td><strong>Key ratios</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Return on Assets</td>
<td>11.51%</td>
<td>11.85%</td>
<td>11.73%</td>
<td>11.66%</td>
<td>11.18%</td>
</tr>
<tr>
<td>Return on Equity</td>
<td>21.66%</td>
<td>27.07%</td>
<td>31.44%</td>
<td>27.94%</td>
<td>25.70%</td>
</tr>
<tr>
<td>Liability ratio</td>
<td>44.73%</td>
<td>59.82%</td>
<td>60.77%</td>
<td>56.50%</td>
<td>56.50%</td>
</tr>
<tr>
<td>Effective Tax Rate</td>
<td>17.24%</td>
<td>17.77%</td>
<td>16.31%</td>
<td>16.80%</td>
<td>16.80%</td>
</tr>
<tr>
<td><strong>Income Statement (CNY: mn)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>9,271</td>
<td>11,013</td>
<td>12,476</td>
<td>14,406</td>
<td>16,634</td>
</tr>
<tr>
<td>- Cost of Goods Sold</td>
<td>6,162</td>
<td>7,043</td>
<td>7,857</td>
<td>8,769</td>
<td>9,947</td>
</tr>
<tr>
<td>Gross Income</td>
<td>3,109</td>
<td>3,970</td>
<td>4,619</td>
<td>5,637</td>
<td>6,687</td>
</tr>
<tr>
<td>- Selling, General &amp; Admin E</td>
<td>1,945</td>
<td>2,427</td>
<td>2,800</td>
<td>3,097</td>
<td>3,576</td>
</tr>
<tr>
<td>Operating Income</td>
<td>1,164</td>
<td>1,543</td>
<td>2,019</td>
<td>2,540</td>
<td>3,111</td>
</tr>
<tr>
<td>- Interest Expense</td>
<td>127</td>
<td>163</td>
<td>305</td>
<td>250</td>
<td>280</td>
</tr>
<tr>
<td>Pretax Income</td>
<td>1,080</td>
<td>1,416</td>
<td>1,733</td>
<td>2,315</td>
<td>2,856</td>
</tr>
<tr>
<td>- Income Tax Expense</td>
<td>186</td>
<td>252</td>
<td>283</td>
<td>389</td>
<td>480</td>
</tr>
<tr>
<td>Income Before XO Items</td>
<td>894</td>
<td>1,164</td>
<td>1,450</td>
<td>1,926</td>
<td>2,376</td>
</tr>
<tr>
<td>- Minority Interests</td>
<td>44</td>
<td>66</td>
<td>82</td>
<td>110</td>
<td>135</td>
</tr>
<tr>
<td>Net Profit</td>
<td>769</td>
<td>1,100</td>
<td>1,388</td>
<td>1,818</td>
<td>2,240</td>
</tr>
</tbody>
</table>

Source: Company, Phillip Securities (HK) Research Estimates

(Financial figures as at 10 April 2015)
We do not base our recommendations entirely on the above quantitative return bands. We consider qualitative factors like (but not limited to) a stock’s risk reward profile, market sentiment, recent rate of share price appreciation, presence or absence of stock price catalysts, and speculative undertones surrounding the stock, before making our final recommendation.

**GENERAL DISCLAIMER**

This publication is prepared by Phillip Securities (Hong Kong) Ltd (“Phillip Securities”). By receiving or reading this publication, you agree to be bound by the terms and limitations set out below.

This publication shall not be reproduced in whole or in part, distributed or published by you for any purpose. Phillip Securities shall not be liable for any direct or consequential loss arising from any use of material contained in this publication.

The information contained in this publication has been obtained from public sources which Phillip Securities has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in this publication are based on such information and are expressions of belief only. Phillip Securities has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in this publication is subject to change, and Phillip Securities shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will Phillip Securities be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages.

Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this material are as of the date indicated and are subject to change at any time without prior notice.

This material is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. The products mentioned in this material may not be suitable for all investors and a person receiving or reading this material should seek advice from a financial adviser regarding the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, before making a commitment to invest in any of such products.

This publication should not be relied upon as authoritative without further being subject to the recipient’s own independent verification and exercise of judgment. The fact that this publication has been made available constitutes neither a recommendation to enter into a particular transaction nor a representation that any product described in this material is suitable or appropriate for the recipient. Recipients should be aware that many of the products which may be described in this publication involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made unless all such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks.

Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of a security. Any decision to purchase securities mentioned in this research should take into account existing public information, including any registered prospectus in respect of such security.

**Disclosure of Interest**

Analyst Disclosure: Neither the analyst(s) preparing this report nor his associate has any financial interest in or serves as an officer of the listed corporation covered in this report.

Firm’s Disclosure: Phillip Securities does not have any investment banking relationship with the listed corporation covered in this report nor any financial interest of 1% or more of the market capitalization in the listed corporation. In addition, no executive staff of Phillip Securities serves as an officer of the listed corporation.

**Availability**

The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities to any registration or licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited (“PSHK”) believed to be accurate. PSHK does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. PSHK (or its affiliates or employees) may have positions in relevant investment products. For details of different product’s risks, please visit the Risk Disclosures Statement on http://www.phillip.com.hk.

© 2015 Phillip Securities (Hong Kong) Limited

**PHILLIP RESEARCH STOCK SELECTION SYSTEMS**

<table>
<thead>
<tr>
<th>Total Return</th>
<th>Recommendation</th>
<th>Rating</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;+20%</td>
<td>Buy</td>
<td>1</td>
<td>&gt;20% upside from the current price</td>
</tr>
<tr>
<td>+5% to +20%</td>
<td>Accumulate</td>
<td>2</td>
<td>+5% to +20% upside from the current price</td>
</tr>
<tr>
<td>-5% to +5%</td>
<td>Neutral</td>
<td>3</td>
<td>Trade within ± 5% from the current price</td>
</tr>
<tr>
<td>-5% to -20%</td>
<td>Reduce</td>
<td>4</td>
<td>-5% to -20% downside from the current price</td>
</tr>
<tr>
<td>&lt;-20%</td>
<td>Sell</td>
<td>5</td>
<td>&gt;20% downside from the current price</td>
</tr>
</tbody>
</table>

Contact Information (Regional Member Companies)

© 2015 Phillip Securities (Hong Kong) Limited
SINGAPORE
Phillip Securities Pte Ltd
Raffles City Tower
250, North Bridge Road #06-00
Singapore 179101
Tel : (65) 6533 6001
Fax : (65) 6535 6631
Website: www.poems.com.sg

HONG KONG
Phillip Securities (HK) Ltd
Exchange Participant of the Stock Exchange of Hong Kong
11/F United Centre 95 Queensway
Hong Kong
Tel (852) 22776600
Fax (852) 28685307
Website: www.phillip.com.hk

INDONESIA
PT Phillip Securities Indonesia
ANZ Tower Level 23B,
Jl Jend Sudirman Kav 33A
Jakarta 10220 – Indonesia
Tel (62-21) 57900800
Fax (62-21) 57900809
Website: www.phillip.co.id

THAILAND
Phillip Securities (Thailand) Public Co. Ltd
15th Floor, Vorawat Building,
849 Silom Road, Silom, Bangrak,
Bangkok 10500 Thailand
Tel (66-2) 6351700 / 22680999
Fax (66-2) 22680921
Website: www.phillip.co.th

UNITED KINGDOM
King & Shaxson Capital Limited
6th Floor, Candlewick House,
120 Cannon Street,
London, EC4N 6AS
Tel (44-20) 7426 5950
Fax (44-20) 7626 1757
Website: www.kingandshaxson.com

AUSTRALIA
PhillipCapital Australia
Level 12, 15 William Street,
Melbourne, Victoria 3000, Australia
Tel (613) 96188238
Fax (613) 92002272
Website: www.phillipcapital.com.au

MALAYSIA
Phillip Capital Management Sdn Bhd
B-3-6 Block B Level 3 Megan Avenue II,
No. 12, Jalan Yap Kwan Seng, 50450
Kuala Lumpur
Tel (603) 21628841
Fax (603) 21665099
Website: www.poems.com.my

JAPAN
PhillipCapital Japan K.K.
Nagata-cho Bldg.,
8F, 2-4-3 Nagata-cho,
Chiyoda-ku, Tokyo 100-0014
Tel (81-3) 35953631
Fax (81-3) 35953630
Website: www.phillip.co.jp

CHINA
Phillip Financial Advisory (Shanghai) Co. Ltd
No 436 Hengfeng Road,
Greentech Unit 604,
Postal code 200070
Tel (86-21) 51699400
Fax (86-21) 63532643
Website: www.phillip.com.cn

THAILAND
Phillip Securities (Thailand) Public Co. Ltd
15th Floor, Vorawat Building,
849 Silom Road, Silom, Bangrak,
Bangkok 10500 Thailand
Tel (66-2) 6351700 / 22680999
Fax (66-2) 22680921
Website: www.phillip.co.th

UNITED KINGDOM
King & Shaxson Capital Limited
6th Floor, Candlewick House,
120 Cannon Street,
London, EC4N 6AS
Tel (44-20) 7426 5950
Fax (44-20) 7626 1757
Website: www.kingandshaxson.com

UNITED STATES
Phillip Futures Inc
141 W Jackson Blvd Ste 3050
The Chicago Board of Trade Building
Chicago, IL 60604 USA
Tel +1.312.356.9000
Fax +1.312.356.9005

AUSTRALIA
PhillipCapital Australia
Level 12, 15 William Street,
Melbourne, Victoria 3000, Australia
Tel (613) 96188238
Fax (613) 92002272
Website: www.phillipcapital.com.au